DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Oxytrol (Oxybutynin Transdermal) - Summary

 


Nutrilib.com
A comprihensive source of nutritional information

OXYTROL SUMMARY

OXYTROL®
Oxybutynin Transdermal System

Oxybutynin acts as a competitive antagonist of acetylcholine at postganglionic muscarinic receptors, resulting in relaxation of bladder smooth muscle. OXYTROL, oxybutynin transdermal system, is designed to deliver oxybutynin continuously and consistently over a 3- to 4-day interval after application to intact skin. OXYTROL is available as a 39 cm2 system containing 36 mg of oxybutynin. OXYTROL has a nominal in vivo delivery rate of 3.9 mg oxybutynin per day through skin of average permeability (interindividual variation in skin permeability is approximately 20%).

OXYTROL is indicated for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and frequency.


See all Oxytrol indications & dosage >>

OXYTROL NEWS HIGHLIGHTS

Published Studies Related to Oxytrol (Oxybutynin Transdermal)

Efficacy and safety of extended-release oxybutynin in combination with tamsulosin for treatment of lower urinary tract symptoms in men: randomized, double-blind, placebo-controlled study. [2008.09]

Intravesical oxybutynin for children with poorly compliant neurogenic bladder: a systematic review. [2008.09]

Intravesical Oxybutynin for Children With Poorly Compliant Neurogenic Bladder: A Systematic Review. [2008.07.17]

Randomized, placebo-controlled trial of the cognitive effect, safety, and tolerability of oral extended-release oxybutynin in cognitively impaired nursing home residents with urge urinary incontinence. [2008.05]

A prospective, randomized, double-blinded placebo-controlled comparison of extended release oxybutynin versus phenazopyridine for the management of postoperative ureteral stent discomfort. [2008.05]

more >>

Clinical Trials Related to Oxytrol (Oxybutynin Transdermal)

A Study Comparing the Efficacy and Safety of OROS® Oxybutynin to That of Ditropan® (Immediate-Release Oxybutynin) for the Treatment of Patients With Urge or Mixed Urinary Incontinence. [Completed]

Transdermal (TDS) Oxybutynin (Oxytrol(r)) in Overactive Bladder [Completed]

Fasting Study of Oxybutynin Chloride ER Tablets 10 mg and Ditropan XL® Tablets 10 mg [Completed]

Food Study of Oxybutynin Chloride ER Tablets 10 mg and Ditropan XL® Tablets 10 mg [Completed]

Fed Study of Oxybutynin Chloride Extended-Release Tablets 10 mg and Ditropan XL® Tablets 10 mg [Completed]

more >>

Page last updated: 2008-11-03

-- advertisement -- The American Red Cross

We comply with
HONcode standard.
Verify here.
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2008